DDMODEL00000073: OGTT Integrated Glucose-Insulin (IGI) Model

  public model
Short description:
This model is the extended version of the previously introduced model for intravenous glucose provocations. In this model, the glucose-insulin system for the oral glucose tolerance test among type 2 diabetics was described. The description of glucose absorption by a chain of transit compartments and a representation of the incretin effect as an Emax function were added. This model was developed based on the data of oral and insulin-modified frequently sampled -intravenous glucose tolerance test in 42 subjects.
Original code
  • An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.
  • Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K, Karlsson MO
  • Journal of clinical pharmacology, 10/2007, Volume 47, Issue 10, pages: 1244-1255
  • Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, University of Uppsala, Friggs Grand 4, Halmstad, Sweden.
  • An integrated model for the glucose-insulin system describing oral glucose tolerance test data was developed, extending on a previously introduced model for intravenous glucose provocations. Model extensions comprised the description of glucose absorption by a chain of transit compartments with a mean transit time of 35 minutes, a bioavailability of 80%, and a representation of the incretin effect, expressed as a direct effect of the glucose absorption rate on insulin secretion. The ability of the model to predict the incretin effect was assessed by simulating the observed difference in insulin response following an oral glucose tolerance test compared with an isoglycemic glucose infusion mimicking an oral glucose tolerance test profile. The extension of the integrated glucose-insulin model to gain information from oral glucose tolerance test data considerably expands its range of applications because the oral glucose tolerance test is one of the most common glucose challenge experiments for assessing the efficacy of hypoglycemic agents in clinical drug development.
Siti Sheikh Ghadzi
Context of model development: Mechanistic Understanding;
Discrepancy between implemented model and original publication: None;
Model compliance with original publication: Yes;
Model implementation requiring submitter’s additional knowledge: No;
Modelling context description: This model is the extended version of the previously introduced model for intravenous glucose provocations. In this model, the glucose-insulin system for the oral glucose tolerance test among type 2 diabetics was described. The description of glucose absorption by a chain of transit compartments and a representation of the incretin effect as an Emax function were added. This model was developed based on the data of oral and insulin-modified frequently sampled -intravenous glucose tolerance test in 42 subjects.;
Modelling task in scope: estimation;
Nature of research: Clinical research & Therapeutic use;
Therapeutic/disease area: Endocrinology;
Annotations are correct.
This model is not certified.
  • Model owner: Siti Sheikh Ghadzi
  • Submitted: Dec 14, 2015 9:51:23 PM
  • Last Modified: Oct 19, 2016 1:34:52 PM
Revisions
  • Version: 11 public model Download this version
    • Submitted on: Oct 19, 2016 1:34:52 PM
    • Submitted by: Siti Sheikh Ghadzi
    • With comment: Updated model annotations.
  • Version: 6 public model Download this version
    • Submitted on: Dec 14, 2015 9:51:23 PM
    • Submitted by: Siti Sheikh Ghadzi
    • With comment: Edited model metadata online.
 
Help